Phase 2/3 Trial of Oral Troriluzole in Easing Alzheimer’s Dementia Fully Enrolled

Phase 2/3 Trial of Oral Troriluzole in Easing Alzheimer’s Dementia Fully Enrolled
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer's disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow memory and cognitive skill loss due to Alzheimer's, and potentially improve these abilities in patients. A preliminary analysis of troriluzole's effects on cognition and brain volume loss, a sign of AD progression, is expected by late December. "We are extremely grateful to all the trial participants and their families, as well as our trial sites, for helping us achieve this milestone," said Irfan Qureshi, MD, Biohaven's vice president of Neurology, said in a press release. "We believe that troriluzole is a promising potential therapy for people suffering from Alzheimer's disease and look forward to the study results, including the interim analysis by the end of this year," he added. Troriluzole, also known as BHV-4157, is a new compound precursor of riluzo
Subscribe or to access all post and page content.